Antiparassitari

MMV006833 is an inhibitor of Plasmodium falciparum. It targets the lipid transfer protein PfSTART1, inhibiting the ring-stage development of Plasmodium falciparum.

CRK12-IN-2, a potent CRK12 inhibitor, has EC50 of 3.2 nM for T. congolense and 0.08 nM for T. vivax; treats trypanosomiasis in animals.

JCP174 is a depalmitoylase inhibitor that enhances Toxoplasma host-cell invasion by targeting TgPPT1.

Rufigallol, an anthraquinone with six OH groups, induces DLC and fluoresces when aggregated, showing antimalarial effects with vitamin C and ketones.

ZY-19489: Antimalarial, potential single-dose cure, FDA orphan drug status.

Mebendazole is a benzimidazole anthelmintic with action on microtubule formation in parasitic worms and is used for treating intestinal worm infections like threadworms and roundworms.

Chloroquine is a 4-aminoquinolone that is used to prevent and treat malaria, caused by parasitic protozoan from the Plasmodium genus. Chloroquine i a schizonticidal agent and is a widely prescribed antimalarial compound. The antiviral activity of chloroquine in vitro has been reported in 1960’s and recent publications have brought attention to its possible benefits in the treatment of COVID-19 patients, infected with the newly emerged coronavirus (SARS-CoV-2). Current evidence shows that chloroquine inhibits SARS CoV-2 entry in host cells by interfering with endocytosis and affecting the glycoprofile on the S-glycoprotein.